Literature DB >> 26468207

Phospholemman is not required for the acute stimulation of Na⁺-K⁺-ATPase α₂-activity during skeletal muscle fatigue.

Palanikumar Manoharan1, Tatiana L Radzyukevich2, Hesamedin Hakim Javadi2, Cory A Stiner3, Julio A Landero Figueroa3, Jerry B Lingrel1, Judith A Heiny4.   

Abstract

The Na(+)-K(+)-ATPase α2-isoform in skeletal muscle is rapidly stimulated during muscle use and plays a critical role in fatigue resistance. The acute mechanisms that stimulate α2-activity are not completely known. This study examines whether phosphorylation of phospholemman (PLM/FXYD1), a regulatory subunit of Na(+)-K(+)-ATPase, plays a role in the acute stimulation of α2 in working muscles. Mice lacking PLM (PLM KO) have a normal content of the α2-subunit and show normal exercise capacity, in contrast to the greatly reduced exercise capacity of mice that lack α2 in the skeletal muscles. Nerve-evoked contractions in vivo did not induce a change in total PLM or PLM phosphorylated at Ser63 or Ser68, in either WT or PLM KO. Isolated muscles of PLM KO mice maintain contraction and resist fatigue as well as wild type (WT). Rb(+) transport by the α2-Na(+)-K(+)-ATPase is stimulated to the same extent in contracting WT and contracting PLM KO muscles. Phosphorylation of sarcolemmal membranes prepared from WT but not PLM KO skeletal muscles stimulates the activity of both α1 and α2 in a PLM-dependent manner. The stimulation occurs by an increase in Na(+) affinity without significant change in Vmax and is more effective for α1 than α2. These results demonstrate that phosphorylation of PLM is capable of stimulating the activity of both isozymes in skeletal muscle; however, contractile activity alone is not sufficient to induce PLM phosphorylation. Importantly, acute stimulation of α2, sufficient to support exercise and oppose fatigue, does not require PLM or its phosphorylation.
Copyright © 2015 the American Physiological Society.

Entities:  

Keywords:  Na+-K+-ATPase α2; fatigue; mammalian skeletal muscle; phospholemman

Mesh:

Substances:

Year:  2015        PMID: 26468207      PMCID: PMC4683216          DOI: 10.1152/ajpcell.00205.2015

Source DB:  PubMed          Journal:  Am J Physiol Cell Physiol        ISSN: 0363-6143            Impact factor:   4.249


  38 in total

1.  Protein kinase Cα activity is important for contraction-induced FXYD1 phosphorylation in skeletal muscle.

Authors:  Martin Thomassen; Adam J Rose; Thomas E Jensen; Stine J Maarbjerg; Laurids Bune; Michael Leitges; Erik A Richter; Jens Bangsbo; Nikolai B Nordsborg
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-09-28       Impact factor: 3.619

2.  Effect of exercise and training on phospholemman phosphorylation in human skeletal muscle.

Authors:  Boubacar Benziane; Ulrika Widegren; Sergej Pirkmajer; Jan Henriksson; Nigel K Stepto; Alexander V Chibalin
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-06-07       Impact factor: 4.310

3.  Role of phospholemman phosphorylation sites in mediating kinase-dependent regulation of the Na+-K+-ATPase.

Authors:  Fei Han; Julie Bossuyt; Jody L Martin; Sanda Despa; Donald M Bers
Journal:  Am J Physiol Cell Physiol       Date:  2010-09-22       Impact factor: 4.249

4.  The alpha(1)- and alpha(2)-isoforms of Na-K-ATPase play different roles in skeletal muscle contractility.

Authors:  S He; D A Shelly; A E Moseley; P F James; J H James; R J Paul; J B Lingrel
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2001-09       Impact factor: 3.619

5.  Fibre type-specific change in FXYD1 phosphorylation during acute intense exercise in humans.

Authors:  Martin Thomassen; Robyn M Murphy; Jens Bangsbo
Journal:  J Physiol       Date:  2013-01-28       Impact factor: 5.182

6.  Exercise-induced increase in maximal in vitro Na-K-ATPase activity in human skeletal muscle.

Authors:  Carsten Juel; Nikolai B Nordsborg; Jens Bangsbo
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-04-10       Impact factor: 3.619

7.  Tissue-specific role of the Na,K-ATPase α2 isozyme in skeletal muscle.

Authors:  Tatiana L Radzyukevich; Jonathon C Neumann; Tara N Rindler; Naomi Oshiro; David J Goldhamer; Jerry B Lingrel; Judith A Heiny
Journal:  J Biol Chem       Date:  2012-11-28       Impact factor: 5.157

8.  Na,K-ATPase in skeletal muscle: two populations of beta-spectrin control localization in the sarcolemma but not partitioning between the sarcolemma and the transverse tubules.

Authors:  M W Williams; W G Resneck; T Kaysser; J A Ursitti; C S Birkenmeier; J E Barker; R J Bloch
Journal:  J Cell Sci       Date:  2001-02       Impact factor: 5.285

9.  Chronic nicotine modifies skeletal muscle Na,K-ATPase activity through its interaction with the nicotinic acetylcholine receptor and phospholemman.

Authors:  Alexander V Chibalin; Judith A Heiny; Boubacar Benziane; Alexander V Prokofiev; Alexander V Vasiliev; Violetta V Kravtsova; Igor I Krivoi
Journal:  PLoS One       Date:  2012-03-19       Impact factor: 3.240

10.  A separate pool of cardiac phospholemman that does not regulate or associate with the sodium pump: multimers of phospholemman in ventricular muscle.

Authors:  Krzysztof J Wypijewski; Jacqueline Howie; Louise Reilly; Lindsay B Tulloch; Karen L Aughton; Linda M McLatchie; Michael J Shattock; Sarah C Calaghan; William Fuller
Journal:  J Biol Chem       Date:  2013-03-26       Impact factor: 5.157

View more
  8 in total

Review 1.  Pivotal role of α2 Na+ pumps and their high affinity ouabain binding site in cardiovascular health and disease.

Authors:  Mordecai P Blaustein; Ling Chen; John M Hamlyn; Frans H H Leenen; Jerry B Lingrel; W Gil Wier; Jin Zhang
Journal:  J Physiol       Date:  2016-07-31       Impact factor: 5.182

2.  Isoform-specific role of Na/K-ATPase α1 in skeletal muscle.

Authors:  Laura C Kutz; Shreya T Mukherji; Xiaoliang Wang; Amber Bryant; Isabel Larre; Judith A Heiny; Jerry B Lingrel; Sandrine V Pierre; Zijian Xie
Journal:  Am J Physiol Endocrinol Metab       Date:  2018-02-13       Impact factor: 4.310

Review 3.  The role of AMPK in regulation of Na+,K+-ATPase in skeletal muscle: does the gauge always plug the sink?

Authors:  Sergej Pirkmajer; Metka Petrič; Alexander V Chibalin
Journal:  J Muscle Res Cell Motil       Date:  2021-01-04       Impact factor: 2.698

4.  Profound regulation of Na/K pump activity by transient elevations of cytoplasmic calcium in murine cardiac myocytes.

Authors:  Fang-Min Lu; Christine Deisl; Donald W Hilgemann
Journal:  Elife       Date:  2016-09-14       Impact factor: 8.140

5.  The Na/K-ATPase α1/Src interaction regulates metabolic reserve and Western diet intolerance.

Authors:  Laura C Kutz; Xiaoyu Cui; Jeffrey X Xie; Shreya T Mukherji; Kayleigh C Terrell; Minqi Huang; Xiaoliang Wang; Jiayan Wang; Adam J Martin; Marco T Pessoa; Liquan Cai; Hua Zhu; Judith A Heiny; Joseph I Shapiro; Gustavo Blanco; Zijian Xie; Sandrine V Pierre
Journal:  Acta Physiol (Oxf)       Date:  2021-04-04       Impact factor: 7.523

6.  Intense interval training in healthy older adults increases skeletal muscle [3H]ouabain-binding site content and elevates Na+,K+-ATPase α2 isoform abundance in Type II fibers.

Authors:  Victoria L Wyckelsma; Itamar Levinger; Robyn M Murphy; Aaron C Petersen; Ben D Perry; Christopher P Hedges; Mitchell J Anderson; Michael J McKenna
Journal:  Physiol Rep       Date:  2017-04

7.  Effect of differentiation, de novo innervation, and electrical pulse stimulation on mRNA and protein expression of Na+,K+-ATPase, FXYD1, and FXYD5 in cultured human skeletal muscle cells.

Authors:  Vid Jan; Katarina Miš; Natasa Nikolic; Klemen Dolinar; Metka Petrič; Andraž Bone; G Hege Thoresen; Arild C Rustan; Tomaž Marš; Alexander V Chibalin; Sergej Pirkmajer
Journal:  PLoS One       Date:  2021-02-26       Impact factor: 3.240

8.  Increased FXYD1 and PGC-1α mRNA after blood flow-restricted running is related to fibre type-specific AMPK signalling and oxidative stress in human muscle.

Authors:  D Christiansen; R M Murphy; J Bangsbo; C G Stathis; D J Bishop
Journal:  Acta Physiol (Oxf)       Date:  2018-02-27       Impact factor: 6.311

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.